Print This Article

Because PRRS shows such ability to mutate, the natural question arises: Can a mass-vaccination program protect animals if a differing strain is introduced? Data from nine independent trials indicate that vaccination with either Ingelvac^® PRRS MLV or Ingelvac^® PRRS ATP provides consistent and significant reduction of lung damage — regardless of the PRR-Schallenge strain used in the trial.

Vaccine reduced PRRS-induced gross lung pathology in all nine trials, showing from 54 percent to 97 percent reduction in gross lesions as compared to non-vaccinated challenge controls.

In addition, research conducted by veterinary pathologist Pat Halbur through Iowa State's Veterinary Diagnostic Lab demonstrates Ingelvac PRRS ATP made a significant contribution to protecting infected pigs from PRRS-induced lung damage as well as improving average daily gain and a significant reduction of viremia in the presence of highly virulent heterologous challenge.

More info

Evaluation of the Efficacy of Ingelvac PRRS MLV and Ingelvac PRRS ATP in Multiple Heterologous Respiratory Challenge Studies. BI-Vetmedica Technical Bulletin BI S124531-TB-5. April 2003.

Evaluation of the Efficacy of Ingelvac PRRS ATP Against Three Different Challenge Strains of PRRS. BI-Vetmedica Technical Bulletin BI S127831-TB-14. March 2003.